[Retracted] The Change of Aqueous Humor Cytokine Levels after Anti-VEGF in Diabetic Macular Edema: A Systematic Review and Meta-Analysis
Table 2
Study characteristics of the nine trials in the meta-analysis.
Country, author, year
Study design
Treatment
S.S
Age (y) (Mean ± SD)
Baseline CFT (μm)
Baseline BCVA, logMAR
Cytokine recorded in our meta-analysis
Follow-up month
Japan, Takuya et al., 2021
Self-control (prospective)
Ranibizumab
25
62.9 ± 9.6
560 ± 166
0.51 ± 0.30
VEGF, IL-6, IL-8, IP-10, and MCP-1
1
Austria, Dominika et al., 2020
Self-control (prospective)
Ranibizumab and dexamethasone
9
66.9 ± 8.8; 64.6 ± 9.0
440 ± 144; 471.3 ± 122.6
0.70; 0.35
VEGF, IL-6, IL-8, and MCP-1
2
Canada, Verena et al., 2020
Self-control (prospective)
Aflibercept
17
57.2 ± 8.1
430.9 ± 85.5
0.39 ± 0.16
VEGF, IL-6, IL-8, IP-10, and MCP-1
1 and 2
Canada, Tina et al., 2019
Self-control (prospective)
Ranibizumab
35
62.4 ± 7.3
480.4 ± 117.4
0.60 ± 0.30
VEGF, IL-6, IL-8, and MCP-1
2
Italy, Mastropasqua et al., 2018
Self-control (prospective)
Aflibercept
20
63.4 ± 7.3
469.43 ± 181.91
0.46 ± 0.24
VEGF, IL-6, IL-8, IP-10, and MCP-1
2
Australia, Shueh et al., 2018
Self-control (prospective)
Ranibizumab
25
63.8 ± 9.6
484.5 ± 134.3
0.48 ± 0.20
IL-6, IL-8, IP-10, MCP-1
2
Canada, Roxane et al., 2018
Self-control (prospective)
Ranibizumab
48
61.9 ± 7.1
495.0 ± 134.6
0.60 ± 0.30
VEGF, IL-6, IL-8, and MCP-1
2
Japan, Tomoyasu et al., 2017
Self-control (prospective)
Ranibizumab
13
62.5 ± 11.9
570.0 ± 109.8
0.47 ± 0.25
IL-6, IL-8, IP-10, and MCP-1
1
Korea, Hee Jin Sohn et al., 2011
Self-control (prospective)
Bevacizumab
11
54.4 ± 10.2
387.7 ± 111.3
0.44 ± 0.32
VEGF, IL-6, IL-8, IP-10, and MCP-1
1
Note. S.S, sample size; the BCVA of two groups in the original text was 74.78 ± 14.85 and 67.22 ± 10.52 presented by Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores. The SD was not available due to lack of raw data.
